![]() |
Accountable Care Organizations...
November 1, 2014 - Featured , In the News / Politics By: Stephanie Chiu and Elissa Tam, PharmD Candidates c/o 2015 — According to the Dartmouth Atlas project, health care spending in the United States has risen dramatically and yet health outcomes are not improving; meanwhile, many other countries that spend far less per person than the United States have better health outcomes.1 Studies have since… |
![]() |
Pediatric Hypertension...
August 1, 2014 - Clinical , Featured By: Anthony Botte and Tyler Valente, PharmD Candidates c/o 2016 – Diseases which are prevalent within the pediatric population require distinct protocols for treatment accompanied by the utmost care and precision. Pediatric hypertension (HTN) is one disease state in particular that has come to the forefront of medical practice in the United States over the… |
![]() |
Quantifying the Benefits of Pharmacist Prescribing Powe...
July 1, 2014 - Featured , Professional Advice / Opinions By Davidta Brown, Senior Staff Editor – The idea of granting pharmacists the right to prescribe, as well as to counsel and dispense, has long been a source of controversy among healthcare professionals. A study out of the University of Alberta in Canada, published online in mid-April, provided some much needed concrete data for an… |
![]() |
Riociguat (Adempas®) New Drug for Pulmonary Hypertens...
April 1, 2014 - Clinical , Featured By: Hayeon Na, Co-Copy Editor [Content-Focused] – On October 8th of 2013, Bayer’s new drug riociguat (Adempas®) was approved for the treatment of patients whose pulmonary hypertension (PH) belongs in WHO groups 1 and 4.1 Riociguat (Adempas®) is a soluble guanylate cyclase (sGC) stimulator, and currently the only one of its kind on the market.… |
![]() |
Surviving APPE Rotations...
January 1, 2014 - Professional Advice / Opinions By: Aleena Cherian, Co-Copy Editor [Graphics-Focused] and Jenny Prakash, PharmD Candidate c/o 2014 – Starting your rotations in 5th year usually brings mixed emotions. On one hand, it’s a relief to finally be finished with labs and D&Ds…imagine, a whole year without any exams! But on the other hand, now you have to test how… |
![]() |
Say Hello to JNC8: New Hypertension Guidelines...
January 1, 2014 - Featured , In the News / Politics By: Frances Trosa PharmD Candidate c/o 2015 – After much anticipation, the report from the Eighth Joint National Committee (JNC 8) has arrived! Panel members appointed to the committee have created evidence – based recommendations to assist physicians in managing hypertensive patients. A major difference between the JNC 7 report and the JNC 8 report… |
![]() |
Direct Association of HIV and Early Kidney Damage in Wo...
January 1, 2014 - Featured , In the News / Politics By: Elizabeth Kopec, PharmD Candidate c/o 2014, South University School of Pharmacy at Columbia, SC – Human immunodeficiency virus (HIV) is a global pandemic, with approximately 35.3 million people infected in 2012. The United States currently has 1.3 million people living with HIV, with 20,000 deaths occurring every year due to acquired immune deficiency syndrome… |
![]() |
Newly Approved: Macitentan (Opsumit®)...
December 1, 2013 - Clinical , Featured By: Rebecca Gilene, PharmD Candidate c/o 2014, St. Louis College of Pharmacy – The FDA approved macitentan (Opsumit®) on October 18, 2013 for the treatment of pulmonary arterial hypertension.1 Pulmonary arterial hypertension, often referred to as PAH, is a disease characterized by high blood pressure in the arteries between the heart and lungs. An increase… |
![]() |
Ponatinib Taken Off the Market...
December 1, 2013 - In the News / Politics By: Sherine Jaison, PharmD Candidate c/o 2015 – The leukemia chemotherapy drug ponatinib (Iclusig) has just been taken off the market. The drug was under investigation by the Food and Drug Administration (FDA) following several reports of serious and life threatening blood clots and narrowing of the blood vessels.1 Ponatinib is a BCR-ABL tyrosine kinase… |
![]() |
Moving Towards Provider Status: An Interview with Sandr...
November 1, 2013 - Professional Advice / Opinions By: Hayeon Na, Co-Copy Editor and Sang Hyo Kim, Staff Editor – In Volume 1 Issue1 of the Rho Chi Post, we were honored to have an interview with Sandra Leal, PharmD, MPH, FAPhA, CDE, and Director of Clinical Pharmacy at El Rio Health Center in Tucson, Arizona. She had started a petition to support… |
![]() |
The Third Wheel or the Steering Wheel? Pharmacists on t...
November 1, 2013 - Professional Advice / Opinions By: Joshua Bliss, PharmD Candidate c/o 2016 – Doctor – a word often utilized by both professionals and the general public alike to describe a physician. “Doctor” finds its origins in the Latin word for “teacher.” The word “physician,” however, carries a more complicated origin. It is derived from Latin’s “physicum,” meaning remedy.1 In Luke… |
![]() |
New Treatment for a Deficiency in Iron-Supplement Thera...
October 1, 2013 - Clinical By: Davidta Brown, Staff Editor – For the estimated 7.5 million individuals in the United States living with iron deficiency anemia (IDA), there is now a new alternative to iron supplements or time-consuming, repetitive infusions. On July 25, 2013, the FDA approved ferric carboxymaltose injection (Injectafer®) for the treatment of IDA, especially in patients who… |
![]() |
Olmesartan Medoxomil Label Revision...
September 1, 2013 - In the News / Politics By: David Ong, PharmD Candidate c/o 2014 – Manipulating the renin-angiotensin system is one of the many ways drugs are used to treat hypertension. By blocking key steps in the renin-angiotensin cascade, blood pressure decrease may be achieved. Angiotensin II receptor blockers (ARBs) represent one of the drug classes that utilize the aforementioned mechanism. ARBs… |
![]() |
Two New Agents for the Treatment of Obesity...
August 1, 2013 - Clinical , Featured By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU – Obesity is defined as having a body mass index (BMI) of 30 kg/m2 or greater. It is thought to be the result of an imbalance between energy intake and energy expenditure, possibly due to a number of genetic and environmental factors.1 It is estimated… |
![]() |
FDA Approves Apixaban For Nonvalvular Atrial Fibrillati...
January 1, 2013 - Clinical , Featured , In the News / Politics By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1 This occurred one month after its approval in Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is… |
![]() |
Tackling America’s Drug Shortage Crisis...
December 1, 2012 - Featured , In the News / Politics , Professional Advice / Opinions By: John S Lim, PharmD Candidate c/o 2013 – America’s focus on healthcare, as well as its position as one of the wealthiest nations of the industrialized world, is incongruous with the consequences of drug shortages suffered by its population. Shortages in pharmaceutical supply compromise quality of life while increasing health care costs. The pharmaceutical… |
![]() |
Adverse Events from Ingestion of OTC Eye Drops and Nasa...
December 1, 2012 - Featured , In the News / Politics By Tasnima Nabi, PharmD Candidate c/o 2016 – The FDA has issued warnings on accidental ingestion of over-the-counter eye drops and nasal sprays because they can cause serious harm in children at and under the age of five. Ingestion of as little as 0.6 ml of OTC nasal decongestants and redness-relief eye drops has been… |
![]() |
Are You Prepared for RSV Season?...
November 1, 2012 - Clinical , In the News / Politics By: Mahdieh Danesh Yazdi, Associate Student Editor – Many of us have prepared for influenza season by receiving the flu vaccine. (If you have not, please speak to your doctor or pharmacist soon! Remember: even if you do not need it for your protection, get it for your patients’ well-being). However, for the youngest members… |
![]() |
Antiplatelet Use Following Acute Coronary Syndromes...
September 1, 2012 - Clinical , Featured By: Addolorata Ciccone, Co-Copy Editor – Acute Coronary Syndromes Acute coronary syndrome (ACS) is a myocardial ischemia caused by obstruction of coronary arteries. ACS is stratified into three types, based on electrocardiogram (EKG) changes and the presence of cardiac biomarkers (e.g. troponin, creatinine phosphokinase, and myoglobin). To guide treatment plans, it is important to identify… |
![]() |
Indications for Dialysis: A Mnemonic And Explanation...
August 1, 2012 - Clinical , Featured By: Neal Shah, Co-Editor-in-Chief – Dialysis is the removal of substances from intravascular circulation by filtration.1 Typically, dialysis is ordered when kidney function declines to 10–15% of normal function.2 The National Kidney Foundation’s Kidney Disease Outcome Quality Initiative (K/DOQI) recommends that planning for dialysis begin when patients reach chronic kidney disease stage 4, which is… |
![]() |
Meet the new Beta 3 Agonist: Mirabegron (Myrbetriq®)...
August 1, 2012 - Clinical , Featured , In the News / Politics By: Steve P. Soman – Mirabegron (Mybetriq®), known also by the brand name Betanis®in Japan, is a new once daily oral drug. First in its class, it is a selective β(3)-adrenoceptor agonist that improves symptoms associated with over active bladder (OAB) such as urinary incontinence, urgency, and urinary frequency by enhancing storage function and relaxing… |
![]() |
Matching Challenge: Over-the-Counter Products...
July 1, 2012 - Puzzles By Mohamed Dungersi, Associate Student Editor – Match the following herbal products with their natural source and reason for use: A. This product is a source of omega-3 fatty acids, primarily docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). It is used to lower triglyceride levels, to lower high blood pressure, and for a variety of… |
![]() |
Matching Challenge: Look-Alike, Sound-Alikes...
June 1, 2012 - Puzzles By: Addolorata Ciccone, Pharm.D. Candidate c/o 2013 – The following medications are easily confused. Try to match each one with its corresponding fun fact. This capsule should be swallowed whole; if chewed or dissolved orally, oropharyngeal anesthesia may occur, which poses a choking hazard. Drinking a glass of water can help bypass this potential adverse… |
![]() |
Risk versus Benefit: Prescription to Over the Counter M...
June 1, 2012 - Professional Advice / Opinions By: Maria A. Sorbera, Pharm.D. Candidate c/o 2013 – Maria Sorbera was the 2011-2012 President of the Rho Chi Beta Theta Chapter at the Arnold & Marie Schwartz College of Pharmacy at Long Island University (LIU). She is a strong advocate of networking with fellow pharmacists regardless of their area of expertise, as well… |
![]() |
Role of Calcium Channel Blockers and Beta Blockers in C...
May 1, 2012 - Clinical , Featured By: Lunbao Huang Pharm D. Candidate c/o 2013 – The seventh report of the Joint National Committee on high blood pressure (JNC-7) states that most classes of antihypertensive drugs such as angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), beta-blockers (BBs), diuretics, and aldosterone-receptor antagonists can be used for hypertensive heart failure patients except… |
![]() |
CHF, a Rare but Serious Presentation of Graves’ disea...
March 1, 2012 - Clinical , Featured By: James Schurr, Pharm.D. Candidate c/o 2014 – Graves’ disease is an autoimmune disorder that results in a state of thyrotoxicosis, or a cause of hyperthyroidism, due to the Immunoglobulin G-mediated agonism of thyroid stimulating hormone (TSH) receptors located on the thyroid. Stimulation of TSH receptors causes an increase in circulating thyroxine (T4) and triiodothyronine… |
![]() |
FDA Approves Edarbyclor®...
January 1, 2012 - Clinical , In the News / Politics By: Gokul Kalla, Pharm.D. Candidate c/o 2013 – Hypertension is a chronic disease that affects one out of every three Americans. Leaving the condition untreated could increase the risk of serious health consequences such as a stroke or a heart attack. On December 21, the FDA approved Takeda Pharmaceuticals’ Edarbyclor® (azilsartan medoxomil and chlorthalidone) for… |
![]() |
Clevidipine in the Management of Hypertensive Emergency...
January 1, 2012 - Clinical , Featured By: Neal Shah – Defined by the Joint National Committee, hypertension (HTN) is a systolic blood pressure (SBP) greater than or equal to 140 mmHg and a diastolic blood pressure (DBP) greater than or equal to 90 mmHg. Patients with Stage 1 HTN have a SBP between 140 and 159 mmHg and DBP between 90… |
![]() |
Ivabradine: A Novel I(f) Blocker for Stable Angina...
December 1, 2011 - Clinical By: Neal Shah – Part I: Preface. Part II: Brief review of cardiac electrophysiology. Part III: Ivabradine as a novel If blocker for the use of stable angina. Part IV: On the horizon: trimetazidine. – PREFACE When viewed anatomically, the heart may seem like a simple organ. However, the electrophysiological aspects of the heart are… |